Malignant Mesothelioma Market Report 2025

The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be credited to increased investments in oncology research, a rise in asbestos-related litigation cases, higher hospital investments, the aging population, and the expansion of AI-driven drug discovery platforms.

The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth during the forecast period can be attributed to the growing adoption of immunotherapy treatments, a stronger emphasis on personalized medicine, increased use of minimally invasive surgical techniques, higher healthcare spending, and a greater number of clinical trials. Key trends expected during this period include advancements in immunotherapy, personalized medicine, early detection efforts, minimally invasive surgery, and the approval of new regulations.

The growing focus on clinical research and development (R&D) efforts is expected to significantly contribute to the expansion of the malignant mesothelioma market in the coming years. Clinical R&D involves conducting scientific studies and trials aimed at developing new drugs, treatments, and medical devices. These efforts assess the safety, efficacy, and potential side effects of new products through controlled clinical trials. The rising demand for innovative treatments, driven by the increasing prevalence of chronic diseases and complex conditions, is propelling these R&D initiatives. Such efforts are crucial in advancing diagnostics, treatments, and targeted therapies for malignant mesothelioma, fostering new approaches to improve early detection, enhance survival rates, and create more effective, less invasive treatment options. For instance, according to a January 2025 report by Anadolu Agency, clinical trials account for nearly 40% of the U.S. pharmaceutical research budget, amounting to about $7 billion annually. As a result, the growing investment in R&D is accelerating the growth of the malignant mesothelioma market.

Companies in the malignant mesothelioma market are concentrating on developing cutting-edge treatments, such as monoclonal antibodies, to inhibit tumor growth and enhance treatment precision. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to detect and target specific antigens, including those found on cancer cells. For example, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody, for treating malignant mesothelioma (excluding malignant pleural mesothelioma). This approval introduced Opdivo as a new treatment option for a condition with no previously established standard treatments. The designation of Opdivo as an orphan drug for this indication highlights its potential to meet an urgent medical need.

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies for $1.2 billion. This acquisition includes all of Gracell’s fully diluted share capital, including the shares represented by American depositary shares. Gracell Biotechnologies, a China-based company, specializes in developing innovative cell therapies for cancer and autoimmune diseases, including malignant mesothelioma.

Major players in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center.

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in malignant mesothelioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the malignant mesothelioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Malignant mesothelioma is a rare and aggressive cancer that mainly affects the mesothelium, a thin tissue layer surrounding most of the internal organs. This cancer typically arises in the lung lining (pleura), but it can also develop in the abdomen (peritoneum), heart (pericardium), or testicles. The primary risk factor for malignant mesothelioma is asbestos exposure, a mineral once extensively used in construction and manufacturing.

Treatment options for malignant mesothelioma include chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. Chemotherapy utilizes drugs to destroy cancer cells, slow down tumor growth, and alleviate symptoms. It is commonly administered when the cancer has spread beyond the point where surgery alone would be effective. These drugs can be given through various methods, including oral, intravenous, injectable, and topical. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, which are used by hospitals, oncology clinics, rehabilitation centers, and research laboratories.

The malignant mesothelioma market research report is one of a series of new reports that provides malignant mesothelioma market statistics, including malignant mesothelioma industry global market size, regional shares, competitors with a malignant mesothelioma market share, detailed malignant mesothelioma market segments, market trends and opportunities, and any further data you may need to thrive in the malignant mesothelioma industry. This malignant mesothelioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The malignant mesothelioma market consists of revenues earned by entities by providing services such as genetic testing and biomarker analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant mesothelioma market includes sales of radiation therapy equipment, biopsy kits, diagnostic imaging systems, genetic testing kits, and home healthcare equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.